ABIVAX

Report Publication Announcement • Mar 12, 2018

Press Release

ABIVAX Upcoming Events

2017 Financial Results to be announced on March 16, 2018

PARIS, Mar. 12, 2018, 8:30 pm. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will participate in upcoming events for investors and business development professionals.

• March 12-14, 2018: BIO-Europe Spring in Amsterdam Prof. Hartmut Ehrlich, M.D., CEO ABIVAX, will give a corporate update presentation on ABIVAX on Tuesday, March 13 at 11:00 in room E105
• March 16, 2018: Full Year 2017 Financial Results
• March 19-20, 2018: BIO Asia International Conference in Tokyo
• April 8-10, 2018: H.C. Wainwright Global Life Sciences Conference in Monaco

About ABIVAX (www.abivax.com/en)

ABIVAX is mobilizing the body's natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

Contacts:

ABIVAX Finance Didier Blondel didier.blondel@abivax.com +33 1 53 83 08 41

Press Relations France ALIZE RP Caroline Carmagnol/Aurore Gangloff abivax@alizerp.com +33 6 64 18 99 59

Investors Relations LifeSci Advisors Chris Maggos chris@lifesciadvisors.com +41 79 367 6254

Press Relations US LifeSci Public Relations Matt Middleman, M.D. matt@lifescipublicrelations.com +1 646 627 8384

Investors and Press Relations Germany MC Services AG Anne Hennecke anne.hennecke@mc-services.eu +49 211 529 252 22